Quinolones are widely used in the treatment of respiratory infections, in large part because of their activity against Streptococcus pneumoniae and other commonly encountered respiratory tract pathogens. Pneumococcal isolates that are resistant to these "respiratory quinolones" have now begun to emerge. Resistance is attributable to mutations affecting the intracellular targets of these drugs, topoisomerase IV and DNA gyrase; drug efflux contributes to quinolone resistance in some isolates. Most commonly, strains fully resistant to the newer quinolones have one or more mutations affecting DNA gyrase and topoisomerase IV. Although various agents of this class exhibit selectivity in primarily targeting one or the other of these enzymes, the passage of isolates in the presence of any agent can result in selection of mutations affecting both enzymes. Quinolone resistance in S. pneumoniae has arisen in heterogeneous genetic backgrounds but, ominously, has now appeared in strains that are well adapted for regional and global transmission.
isolates have begun to appear. Here I describe the mechanisms of quinolone resistance in S. pneumoniae and review current understanding of the origins of resistant strains.
MECHANISMS OF ACTION
The cellular targets of the quinolone antimicrobials are the bacterial type II topoisomerases. These enzymes introduce breaks in double-stranded DNA, allow passthrough of a nearby strand of DNA, and then reseal the break [8] [9] [10] . Because of the highly condensed state in which DNA exists in the cell and the intertwining of DNA strands resulting from replication, these functions are necessary for DNA replication and transcription to be carried out effectively. DNA gyrase and topoisomerase IV, the topoisomerase enzymes targeted by the quinolones, are both tetrameric structures, each composed of 2 subunit pairs. These subunits are designated GyrA and GyrB, for DNA gyrase, and ParC and ParE, for topoisomerase IV. The quinolones are believed to act through formation of a ternary complex involving the drug, the topoisomerase, and DNA. Binding by the quinolone is believed to stabilize strand breaks, preventing further DNA replication and repair, thus inhibiting growth. Mechanisms ultimately leading to cell death are incompletely understood [11] . 
MECHANISMS OF RESISTANCE
Resistance to quinolone antimicrobials in S. pneumoniae can result from target mutations in the genes encoding subunits of topoisomerase IV (primarily parC) or DNA gyrase (primarily gyrA), or both. Enhanced quinolone efflux, resulting in reduced intracellular drug concentrations, also contributes modestly to resistance. Other theoretical mechanisms of antimicrobial resistance, such as target protection [12] or drug inactivation, have not been implicated as contributors to quinolone resistance in pneumococci.
Mechanisms of quinolone resistance in S. pneumoniae have been explored by use of several approaches. Resistant mutants can be selected in vitro after exposure of a test strain to the antimicrobial of interest, either at selected concentrations (usually fixed multiples of the MIC) or after serial passage in incremental concentrations of the drug. Quinolone-resistant colonies derived from such experiments can be examined for alterations in level of drug efflux and for mutations in topoisomerase subunit genes.
For practical purposes, most projects that use DNA sequencing focus on specific regions of these genes, termed the "quinolone resistance-determining regions" (QRDRs), where mutations leading to resistance have clustered. The primary target of a quinolone antimicrobial-for example, parC or gyrA-is inferred from the location of mutations leading to the first increments in drug resistance. These same tools can be applied to the study of quinolone-resistant clinical isolates of S. pneumoniae. The availability of resistant clinical isolates permits assessment of how resistance may have evolved from exposure of individual patients or of populations to quinolones in actual therapeutic use. Furthermore, the ability to prepare topoisomerases in purified and biologically active form has allowed quantitative evaluation of the inhibitory activities of various quinolones on enzymatic functions. DNA gyrase activity can be measured by means of assays of supercoiling of relaxed plasmid DNA, and topoisomerase IV activity can be measured by decatenation of highly interlocked chains of kinetoplast DNA [13] .
QUINOLONE RESISTANCE AMONG CLINICAL ISOLATES
Starting with a collection of 4650 clinical isolates of S. pneumoniae recovered between 1994 and 2000, Brueggemann et al. [6] searched for mutations affecting DNA gyrase or topoisomerase IV among isolates with ciprofloxacin MICs of у4 mg/ mL and from a sample of more susceptible organisms. During this period, the proportion of isolates with ciprofloxacin MICs of у4 mg/mL remained relatively stable (1.2% in 1994-1995 and 1.4% in 1999-2000) , and the incremental difference in levofloxacin resistance (0.3%-0.7%) did not achieve statistical significance. Mutations in parC or gyrA were not seen in isolates with a ciprofloxacin MIC of р1 mg/mL. However, mutations were found in 11% of 72 isolates with MICs of 2 mg/mL, in 36% of 36 isolates with MICs of 4 mg/mL, and 97% of 29 isolates with MICs of 14 mg/mL. About two-thirds of the pneumococci with mutations had changes in parC only, most commonly resulting in the amino acid substitution Ser79Phe, whereas only 8.2% had mutations in gyrA only (Ser81Phe or Ser81Tyr); 24.5% had mutations in both parC and gyrA [6] .
The results of this study also illustrated the relative effects of mutations in parC and gyrA on the activities of 4 fluoroquinolones. Compared with the mean MICs of the entire population of 4650 isolates, ciprofloxacin MICs were increased 4.9-fold in isolates with a parC mutation, whereas MICs of the other agents were increased minimally (2-fold) [6] (figure 1).
These data support the conclusion that topoisomerase IV is the primary target of ciprofloxacin in S. pneumoniae. In contrast, mutations in gyrA alone had the greatest impact on gatifloxacin and moxifloxacin MICs, compared with the population mean MICs for these antimicrobials. It is important to note, however, that although the fold increase in MIC was greatest for these 8-methoxy fluoroquinolones, the geometric mean MICs of gatifloxacin (3.5 mg/mL) and moxifloxacin (1.7 mg/mL) in the gyrA mutants were still lower than those of ciprofloxacin and levofloxacin (8 mg/mL and 10 mg/mL, respectively) [6] .
Jones et al. [14] studied 30 isolates that were not susceptible to у1 of several quinolones and 39 isolates that were susceptible to levofloxacin that were identified from 8419 S. pneumoniae isolates collected during a worldwide surveillance program. The most common pattern of mutations associated with reduced susceptibility (encountered in 17 isolates), involved single mutations in parC (Ser79Phe, or 1 strain with Asp78Asn) and in gyrA (Ser81Phe). Single mutations in gyrA (Ser81Phe) plus double mutations in parC (Ser79Phe, Lys137Asn, Asp83Asn, Asp78Asn, or Arg95Cys) were found in 8 strains. Five strains had only single mutations in gyrA. Although a number of strains harbored single or combination mutations in parE or gyrB of topoisomerase IV and DNA gyrase, respectively, the authors were unable to assign to these a specific contributory role in reduced quinolone susceptibility [14] .
For 10 of 16 ofloxacin-resistant pneumococcal isolates collected in the United States and studied by Weigel et al. [15] , fluoroquinolone resistance was the only significant resistance trait represented. Compared with a wild type strain, isolates with double mutations (in parC and in gyrA) had 8-fold to 32-fold increases in the gatifloxacin, gemifloxacin, and levofloxacin MICs, 8-fold to 64-fold increases in the moxifloxacin MIC, and 32-fold to 128-fold increases in the sparfloxacin MIC. The nature of the mutation or other background characteristics of the host strain had an appreciable effect on the levels of resistance observed. For example, one strain with mutations in gyrA (Glu85Lys) and parC (Ser79Phe) was 4-fold more resistant to all of the drugs mentioned above than was another strain with Ser81Phe and Asp83Tyr substitutions in the genes coding for DNA gyrase and topoisomerase IV, respectively [15] .
This study did provide evidence that gyrB and parE mutations can contribute to quinolone resistance [15] . In particular, 1 isolate with mutations affecting GyrB (Glu474Lys) and ParC (Ser79Phe) exhibited resistance to levofloxacin (MIC, 8 mg/mL) and differential effects on its susceptibilities to gatifloxacin (MIC, 2 mg/mL) and moxifloxacin (MIC, 0.25 mg/mL).
Mutations in parC are found commonly among strains of S. pneumoniae with levofloxacin MICs at the upper end of the susceptible range. However, these single mutations appear, in most instances, to be insufficient on their own to confer full resistance. For example, Blosser et al. [16] identified parC mutations in 18 of 20 isolates with levofloxacin MICs of 2 mg/mL, whereas all but 1 of 42 isolates with MICs of у4 mg/mL had mutations in gyrA as well as parC. Jorgensen et al. [17] found parC mutations in 3 S. pneumoniae isolates with levofloxacin MICs of 4 mg/mL, whereas 5 strains with MICs of 8-16 mg/mL harbored mutations in gyrA and either parC or parE.
An efflux pump identified in S. pneumoniae, PmrA, has 24% amino acid identity with efflux pumps of other gram-positive bacteria: NorA in Staphylococcus aureus and Bmr in Bacillus subtilis [18] . Inhibition of this efflux pump by reserpine has the greatest effect on the ciprofloxacin MICs and little effect on the moxifloxacin MICs [19] . Brenwald et al. [20] examined 273 clinical isolates of S. pneumoniae with ciprofloxacin MICs of 11 mg/mL or norfloxacin MICs of 18 mg/mL and found that ∼45% showed a у4-fold reduction of MICs in the presence of reserpine, consistent with activity of an efflux pump. A similar approach yielded evidence of reserpine-inhibitable efflux in 31% of 74 isolates of levofloxacin-susceptible pneumococci [21] . Bast et al. [22] noted that reserpine substantially enhanced quinolone activity in 37% of pneumococci with ciprofloxacin MICs of 4-8 mg/mL but in only 11% of isolates with MICs of р2 mg/mL and in 7% of those with MICs of 18 mg/mL.
There is some evidence that pumps other than PmrA may effect the efflux of quinolones in pneumococci. Pestova et al. [23] selected ethidium bromide-resistant mutants from a pmrA-knockout strain of S. pneumoniae and showed that the activity of quinolones could be enhanced ∼2-fold by incubation with reserpine. These experiments suggested the presence of a reserpine-inhibitable pump capable of extruding quinolones that was distinct from PmrA.
STUDIES WITH QUINOLONE-RESISTANT MUTANTS SELECTED IN VITRO
Gootz et al. [24] selected first-step mutants of S. pneumoniae with reduced susceptibility to ciprofloxacin (MICs of 4-8 mg/ mL) at rates of ∼1 in 10 9 cfu plated in the presence of the quinolone at a concentration 4 times the MIC. The resulting organisms were found to have mutations in parC. A second round of selection on plates containing ciprofloxacin at a concentration 4 times the MIC of the less-susceptible first-step mutants resulted in the selection of second-step mutants at about the same rate, with MICs in the range of 32-256 mg/mL. These second-step mutants were found to have alterations in both parC and gyrA. Such experiments reveal that although parC may be the primary target of ciprofloxacin, continued exposure to this agent does permit the selection of colonies with mutations in a secondary target (gyrA) as well.
The ease with which resistant mutants can be selected by use of various concentrations of quinolones varies with the agent. Fukuda and Hiramatsu [25] found that resistant S. pneumoniae mutants could be selected on plates containing sparfloxacin at concentrations as high as 16 times the MIC. In contrast, mutants resistant to ciprofloxacin or trovafloxacin could not be selected at concentrations of 14 times the MIC, and mutants resistant to levofloxacin could not be obtained at concentrations of 12 times the MIC. At twice the MIC, resistance to gatifloxacin occurred at a rate of !1.1 in 10 9 cfu. Furthermore, the nature of the mutations observed also varied with the use of different quinolones. Mutants selected on plates containing ciprofloxacin, norfloxacin, trovafloxacin, and levofloxacin had mutations in parC, whereas those selected on gatifloxacin or sparfloxacin had mutations in gyrA [25] . As is the case with gatifloxacin, plating on moxifloxacin (also a C-8-methoxy quinolone) permitted selection of first-step mutants in gyrA, rather than in parC [26] . Another way of selecting quinolone-resistant pneumococci in vitro is by sequential passage in progressively increasing concentrations of a single antimicrobial agent. Boos et al. [27] passed 6 isolates in increasing concentrations of ciprofloxacin, sparfloxacin, gatifloxacin, moxifloxacin, and gemifloxacin for 10 days. The MICs for the organisms recovered after passage had increased to 8 mg/mL for gemifloxacin, 16 mg/mL for sparfloxacin, and 64 mg/mL for ciprofloxacin, gatifloxacin, and moxifloxacin. Mutations in gyrA, parC, or both were found, and quinolone resistance was stable after the passage of strains in the absence of drug. No drug appeared to have any distinct advantage in terms of a lower potential to select for resistant strains.
Davies et al. [28] performed a similar experiment, taking 10 isolates of S. pneumoniae through 50 sequential passages in subinhibitory concentrations of quinolones, followed by 10 passages in antibiotic-free medium. When selection was undertaken in the presence of levofloxacin, strains with final MICs of 4-64 mg/mL were obtained. Two of the 10 strains harbored mutations in gyrA only (MICs of 4 mg/mL). Mutations in gyrA plus parC were found in the strain with the highest MIC (64 mg/mL). Other combinations of mutations that were encountered included parC and gyrB, parE and gyrA, and parE and gyrB.
Transformation experiments have provided proof that mutations affecting DNA gyrase or topoisomerase IV are responsible for quinolone resistance. Transformation of mutant parC genes into wild type pneumococci resulted in 4-fold increases in the ciprofloxacin MICs and 2-fold increases in the levofloxacin and sparfloxacin MICs [29, 30] . Transformation with mutant gyrA alone increased moxifloxacin and sparfloxacin MICs у4-fold, and transformation with doubly mutated gyrA and parC genes provided dramatic increases in moxifloxacin, sparfloxacin, and ciprofloxacin MICs (to у64 mg/mL) [30] .
STUDIES OF RESISTANCE THAT USE PURIFIED ENZYMES
Advances in the ability to express, purify, and reconstitute enzymatically active DNA gyrase and topoisomerase IV have provided another means of directly studying the effects of quinolones against pneumococcal enzymes. Under these experimental conditions, topoisomerase IV activity tends to be more sensitive to inhibition by quinolones than is DNA gyrase activity. However, the magnitude of differences in IC 50 values between DNA gyrase and topoisomerase IV depends on the structures of various compounds.
Kishii et al. [31] found that the ratio of the IC 50 for DNA gyrase to the IC 50 for topoisomerase IV for ciprofloxacin was ∼20, reflecting selectivity favoring the latter enzyme. In contrast, this ratio was ∼3.6 for gatifloxacin and moxifloxacin, for which the primary target in pneumococci appears to be DNA gyrase. These investigators provided experimental evidence that the C-8-methoxy groups of the latter compounds contribute to the enhanced selectivity of gatifloxacin and moxifloxacin for DNA gyrase. They found that substitution of the methoxy group of gatifloxacin with an H group resulted in an IC 50 ratio of ∼16, close to that for ciprofloxacin, reflecting relative loss of activity against DNA gyrase. On the other hand, the addition of a C-8-methoxy group to the ciprofloxacin molecule (AM-1147; figure 2) reduced the IC 50 ratio to 4.8-that is, not very different from those of moxifloxacin and gatifloxacin. In these experiments, the IC 50 ratio for levofloxacin, 5.6, was intermediate between those of ciprofloxacin and moxifloxacin but closer to the latter [31] .
The influence of structure on target preference is further revealed by studies comparing ciprofloxacin with a C-7-substituted (4-(4-aminophenylsulfonyl)-1-piperazinyl) ciprofloxacin-like compound, designated NSFQ-105 [13] . For ciprofloxacin, the IC 50 for supercoiling (DNA gyrase activity) was 80 mmol/L, and the IC 50 for decatenation (topoisomerase IV activity) was 5 mmol/L, giving a ratio of 16, virtually identical to the results obtained by others [31] . However, for N-sulfanilylpiperazinyl fluoroquinolone (NSFQ)-105, the IC 50 values for supercoiling and decatenation were 5-10 mmol/L and 10-20 mmol/L, respectively [13] . Thus, the structural modification at C-7 to yield NSFQ-105 resulted in a complete reversal of target sensitivity, with a preference toward DNA gyrase.
Not all investigators have reported such marked differences in the selectivity of various quinolones for topoisomerase IV versus DNA gyrase inhibition, as determined by use of reconstituted enzymes. Yague et al. [32] confirmed the greater in- Figure 2 . Chemical structures of ciprofloxacin and ciprofloxacin analogues used in studies with purified topoisomerase IV and DNA gyrase [13, 31] .
hibitory potencies of several quinolones against topoisomerase IV, compared with DNA gyrase. They also provided a rank order of potency against the catalytic activities of both enzymes: gemifloxacin was the most potent inhibitor, followed by moxifloxacin and gatifloxacin, and ciprofloxacin and levofloxacin were the weakest inhibitors. However, the IC 50 ratios were ∼2 for all 5 antimicrobial agents tested. In the presence of purified DNA gyrase, gemifloxacin followed by moxifloxacin were most potent in stimulating DNA breakage; in the presence of topoisomerase IV, gemifloxacin followed by moxifloxacin and ciprofloxacin were most active [32] . In the presence of reconstituted enzymes from strains with well-characterized mutations in either gyrA or parC, the ability of all drugs to stimulate DNA breakage was markedly reduced, with gemifloxacin remaining the most active.
POTENTIAL FOR FURTHER RESISTANCE AND SPREAD
Although resistance to the "respiratory quinolones" (i.e., those with activity against S. pneumoniae and other commonly encountered respiratory tract pathogens) among clinical isolates of S. pneumoniae remains very uncommon in most regions of the world, there is evidence that first-step topoisomerase IV mutations are reasonably common. Davies et al. [33] sampled a large collection of levofloxacin-susceptible pneumococci and found no QRDR mutations in isolates with levofloxacin MICs of 0.5 mg/mL, whereas 6.1% of isolates with MICs of 1 mg/mL and 71% of those with MICs of 2 mg/mL had mutations in parC. Extrapolating from the MIC distribution of the entire population of isolates, these investigators estimated that ∼4.5% of levofloxacin-susceptible pneumococci carried "silent" mutations in parC. Presumably, this subgroup of organisms constitutes a population at risk of developing resistance to this and other respiratory quinolones as the result of a second-step mutation.
Available evidence suggests that quinolone resistance has arisen in genetically heterogeneous strains of pneumococci. Quinolone resistance has been noted in both penicillin-susceptible and penicillin-resistant strains [34] . As mentioned earlier, in some isolates, quinolone resistance may be the only clinically relevant antimicrobial resistance trait [15] . Liñares et al. [35] noted 17 distinct PFGE patterns among 18 isolates of S. pneumoniae with ciprofloxacin MICs of у4 mg/mL. A study of 25 levofloxacin-resistant pneumococci recovered in the United States during 1998-1999 found only 3 pairs of isolates to be indistinguishable or closely related genetically [5] .
However, surveillance studies have also documented the occurrence of quinolone-resistant isolates among strains representing international epidemic clones of S. pneumoniae [36] . The appearance of quinolone resistance in representatives of the Spain 23F -1 and Spain 9V -3 international clones of multidrugresistant pneumococci is a cause for concern regarding the future dissemination of these organisms [37] . Indeed, studies from Hong Kong have confirmed the regional dissemination of a multidrug-resistant pneumococcal clone, which was designated Hong Kong 23F -1 [38] . Twenty-two of the 24 quinoloneresistant isolates were indistinguishable by PFGE. By multilocus sequence typing, these strains were identical to the clone designated Spain 23F -1.
CONCLUSIONS
Quinolone resistance in pneumococci can be attributed to mutations affecting the intracellular targets of these drugs, either topoisomerase IV and/or DNA gyrase. The activity of one or more efflux pumps contributes modestly to resistance to these agents but may play a facilitating role in the selection of quinolone-resistant mutants. Mutations affecting the subunit ParC, the primary target of ciprofloxacin, significantly reduce the activity of this agent in vitro. Isolates with single parC mutations often remain susceptible to levofloxacin and the other respiratory quinolones in common use, although the levofloxacin MICs are usually at the upper end of the susceptible range. In contrast, single mutations affecting gyrA often confer resistance to these agents, and isolates with у1 mutation in both gyrA and parC (or in the complementary subunit genes gyrB and parE) have the highest levels of resistance. Quinolone structures, such as substituents at positions C-7 and C-8, affect the topoisomerase target selectivity of these agents. However, although the various quinolones differ in their target selectivities, as determined by the nature and ease of selection of first-step mutants and by their in vitro enzyme inhibitory activities, when pneumococci are subjected to serial passage in incrementally increasing concentrations of antimicrobials, any differences between the drugs become less apparent.
Quinolone-resistant pneumococci are a heterogeneous group of organisms. However, there is already evidence of clonal spread of quinolone-resistant strains regionally. The development of quinolone resistance in strains of the well-established international epidemic clones portends the further spread of quinolone resistance in this species.
